Timmermans P B, Thoolen M J
E.I. du Pont de Nemours & Company (Inc.), Medical Products Department, Wilmington, DE 19898.
Eur J Pharmacol. 1987 Aug 11;140(2):133-42. doi: 10.1016/0014-2999(87)90799-0.
Intravenous (i.v.) dobutamine and BDF 6143 were partial agonists in increasing diastolic pressure in beta-adrenoceptor-blocked pithed rats. The log dose-pressor effect curves were not influenced by yohimbine (1 mg/kg i.v., -15 min) but were markedly shifted to the right by prazosin (0.1 mg/kg i.v., -15 min) indicating the exclusive involvement of alpha 1-adrenoceptors. Nifedipine (0.1-1 mg/kg i.a., -15 min) non-competitively inhibited the pressor effects of dobutamine and BDF 6143 as well as of the alpha 2-adrenoceptor agent B-HT 920 with equal potency. The -log ED50 values calculated for nifedipine amounted to 6.25 +/- 0.12, 6.16 +/- 0.14 and 6.20 +/- 0.10, respectively. Phenoxybenzamine (3 or 10 micrograms/kg i.v., -60 min) did not affect the effectiveness of nifedipine (0.1 mg/kg) to inhibit the pressor effects of dobutamine and BDF 6143. Following treatment with Bay k 8644 (1 mg/kg i.a., -15 min), the log dose-pressor effect curves for dobutamine and BDF 6143 were shifted to the left and the maximum responses were elevated. Our findings suggest that the alpha 1-adrenoceptor-induced pressor effects of dobutamine and BDF 6143 rely heavily on the influx of Ca2+, and are indistinguishable in this respect from the effects initiated by alpha 2-adrenoceptor stimulation. The data further support the view that the sensitivity of alpha-adrenoceptor-mediated pressor effects to inhibition by Ca2+ entry blockers depends on the extent to which Ca2+ influx contributes to the overall response and is not determined by the intrinsic activity or by the receptor reserve of the alpha-adrenoceptor agonist.
静脉注射多巴酚丁胺和BDF 6143对β肾上腺素受体阻断的脊髓横断大鼠舒张压升高具有部分激动作用。对数剂量-升压效应曲线不受育亨宾(静脉注射1 mg/kg,-15分钟)影响,但明显右移于哌唑嗪(静脉注射0.1 mg/kg,-15分钟),表明仅涉及α1肾上腺素受体。硝苯地平(腹腔注射0.1 - 1 mg/kg,-15分钟)以同等效力非竞争性抑制多巴酚丁胺、BDF 6143以及α2肾上腺素受体激动剂B-HT 920的升压效应。计算得出的硝苯地平-log ED50值分别为6.25±0.12、6.16±0.14和6.20±0.10。酚苄明(静脉注射3或10 μg/kg,-60分钟)不影响硝苯地平(0.1 mg/kg)抑制多巴酚丁胺和BDF 6143升压效应的有效性。用Bay k 8644(腹腔注射1 mg/kg,-15分钟)处理后,多巴酚丁胺和BDF 6143的对数剂量-升压效应曲线左移,最大反应升高。我们的研究结果表明,多巴酚丁胺和BDF 6143由α1肾上腺素受体介导的升压效应在很大程度上依赖于Ca2+内流,在这方面与α2肾上腺素受体刺激引发的效应无法区分。数据进一步支持了以下观点,即α肾上腺素受体介导的升压效应对Ca2+内流阻滞剂抑制的敏感性取决于Ca2+内流对总体反应的贡献程度,而非由α肾上腺素受体激动剂的内在活性或受体储备决定。